Medincell Sa Stock Target Price
| MDCLF Stock | USD 34.39 0.00 0.00% |
As of the 6th of February, MedinCell secures the Standard Deviation of 48.34, mean deviation of 11.72, and Risk Adjusted Performance of 0.1024. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of MedinCell SA, as well as the relationship between them. Please verify MedinCell SA mean deviation, variance, as well as the relationship between the Variance and maximum drawdown to decide if MedinCell SA is priced some-what accurately, providing market reflects its recent price of 34.39 per share. Given that MedinCell SA has variance of 2336.49, we recommend you to check MedinCell's last-minute market performance to make sure the company can sustain itself at a future point.
MedinCell's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing MedinCell's valuation are provided below:MedinCell SA does not presently have any fundamental ratios for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. MedinCell |
Did you try this?
Run Idea Analyzer Now
Idea AnalyzerAnalyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |
| All Next | Launch Module |
MedinCell Fundamentals
| Return On Asset | -0.4 | |||
| Operating Margin | (3.25) % | |||
| Current Valuation | 190.33 M | |||
| Shares Outstanding | 25.22 M | |||
| Shares Owned By Insiders | 47.61 % | |||
| Shares Owned By Institutions | 19.00 % | |||
| Price To Book | 34.52 X | |||
| Price To Sales | 31.58 X | |||
| Revenue | 4.09 M | |||
| Gross Profit | 4.09 M | |||
| EBITDA | (21.45 M) | |||
| Net Income | (24.81 M) | |||
| Cash And Equivalents | 34.39 M | |||
| Cash Per Share | 1.38 X | |||
| Total Debt | 16.25 M | |||
| Debt To Equity | 4.86 % | |||
| Current Ratio | 2.84 X | |||
| Book Value Per Share | (1.04) X | |||
| Cash Flow From Operations | (21.36 M) | |||
| Earnings Per Share | (0.88) X | |||
| Number Of Employees | 151 | |||
| Beta | 1.02 | |||
| Market Capitalization | 244.65 M | |||
| Total Asset | 44.3 M | |||
| Z Score | 9.0 | |||
| Net Asset | 44.3 M |
About MedinCell Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze MedinCell SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MedinCell using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MedinCell SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in MedinCell Pink Sheet
MedinCell financial ratios help investors to determine whether MedinCell Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in MedinCell with respect to the benefits of owning MedinCell security.